Trial Profile
A Phase 1b, Double-Blind, Randomized, Placebo-Controlled, Three Segment Cross-Over Study Investigating Oral Steady-State Pharmacokinetics And Hypoalgesic Effect Of 20 Mg Omnitram And 50 Mg Tramadol In Normal Human Subjects Made Cyp2d6 Deficient By Paroxetine
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Desmetramadol (Primary) ; Tramadol
- Indications Pain
- Focus First in man; Therapeutic Use
- Sponsors Syntrix Biosystems
- 31 Oct 2019 According to an Syntrix Pharmaceuticals media release, positive desmetramadol trial was featured on the October 2019 cover of The Journal of Pain, the official journal of the American Pain Society.
- 31 Oct 2019 According to an Syntrix Pharmaceuticals media release, the company will present an overview of desmetramadol and positive first-in-man trial results at the 2019 Pain Management SUMMIT.
- 04 Jun 2019 Results from this and another phase I trial (profile 247946) presented in a Syntrix Biosystems media release.